ClinicalTrials.gg
CompletedNCT01533116Updated Nov 16, 2015Results posted

Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide

A Phase 1 interventional study of BIA 9-1067 and Placebo in Parkinson Disease, sponsored by Bial - Portela C S.A.. Completed at 1 site in Canada. Open to participants aged 25 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-11-16.

Sponsored by Bial - Portela C S.A. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
25 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing opicapone in Parkinson Disease — none open to participants now, none under way, none of them phase 3. opicapone · Parkinson Disease.

Enrollment
15th of 38
52 · median 28
Started
2009
with 9 others
Phase 1
27 of 38
none open now
Registered
16th of 38
by date
Lead sponsor
33 of 38
Bial - Portela C S.A.

Among the 38 studies testing opicapone in Parkinson Disease, this one is the 15th largest by enrollment, is one of 10 that started in 2009, is one of 27 in phase 1, and was the 16th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 38 studies testing opicapone in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About opicapone

opicapone: first FDA approval 2020 (ONGENTYS), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 25 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 38 studies testing opicapone in Parkinson Disease as a file.
02

Study summary

To investigate the effect of BIA 9-1067 in steady-state conditions on the levodopa pharmacokinetics

Read the detailed description

Single centre, randomized, double-blind, gender-balanced, placebo-controlled study in 4 groups of healthy subjects

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Parkinson Disease
  • BIA 9-1067
04

Who can participate

Ages eligible
25 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Availability for the entire study period and willingness to adhere to the protocol requirements as evidenced by the form (ICF) duly read, signed and dated by the volunteer prior to participation in the study.
  • Male or female volunteers.
  • Volunteers of at least 25 years of age but not older than 45 years.
  • Volunteers with (BMI) greater than or equal to 19 and below 30 kg/m2.
  • Volunteers who were healthy as determined by pre-study (at screening) medical history, physical examination, vital signs, complete neurological examination and 12-lead .
  • Volunteers who had clinical laboratory test results judged clinically acceptable (within the laboratory's stated normal range; if not within this range, they must had been without any clinical significance) at screening and admission to first treatment period.
  • Volunteers who had negative tests for surface antigen (HBsAg), anti- antibodies (HCV Ab), and Human immunodeficiency viruses -1 and -2 antibodies (-1 and HIV-2 Ab) at screening.
  • Volunteers who had negative screen of ethyl alcohol and drugs of abuse at screening and admission to the treatment period.
  • Volunteers who were non- or ex-smokers. For the purpose of this study, an ex-smoker is defined as someone who completely stopped smoking for at least 3 months before day 1 of this study.
  • Due to unknown risks and potential harm to the unborn fetus, sexually active men or women must have agreed to use a medically acceptable form of throughout the study.
  • If female of , she had a negative HCG beta serum pregnancy test at screening and admission to each treatment period.
  • The informed consent form must have been signed by all volunteers, prior to their participation in the study.

Exclusion criteria

Exclusion Criteria:

  • Volunteers who did not conform to the above inclusion criteria, or in case of
  • Volunteers who had a surgical history.
  • Volunteers who had a clinically relevant family history.
  • Volunteers who had a history of relevant atopy.
  • Volunteers who had a significant infection or known inflammatory process at screening or admission to the treatment period.
  • Volunteers who had acute gastrointestinal symptoms at the time of screening or admission to the treatment period (e.g., nausea, vomiting, diarrhoea, heartburn).
  • Volunteers who were vegetarians, vegans or have medical dietary restrictions.
  • Volunteers who could not communicate reliably with the investigator.
  • Volunteers who were unlikely to co-operate with the requirements of the study.
  • History of to BIA 9-1067, tolcapone, entacapone, levodopa, benserazide or any related products (including of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs.
  • Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects.
  • History of significant gastrointestinal, liver or kidney disease that may affect drug bioavailability.
  • Presence or history of significant cardiovascular, pulmonary, hematologic, neurologic, psychiatric, lymphatic, musculoskeletal, genitourinary, endocrine, immunologic, dermatologic or connective tissue disease.
  • Suicidal tendency, history of or disposition to seizures, state of confusion, clinically relevant psychiatric diseases.
  • Presence of significant heart disease or disorder according to .
  • Presence of suspicious undiagnosed skin lesions or a history of melanoma.
  • Previous history of Neuroleptic Malignant Syndrome (NMS) and/or nontraumatic rhabdomyolysis.
  • History of significant glaucoma.
  • Used of prescription medications including monoamine oxidase (MAO) inhibitors within 28 days before day 1 of the study.
  • Used of over-the-counter (OTC) products within 7 days before day 1 of the study.
  • Maintenance therapy with any drug, or significant history of drug dependency (drug abuse) or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic).
  • Any clinically significant illness in the previous 28 days before day 1 of this study.
  • Volunteers who took an Product (in another clinical trial) or donated 50 mL or more of blood in the previous 28 days before day 1 of this study.
  • Poor motivation, intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with the protocol requirements or inability to cooperate adequately, inability to understand and to observe the instructions of the physician.
  • Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before day 1 of this study.
  • Positive urine screening of ethyl alcohol or drugs of abuse at admission to the treatment period.
  • Any history of tuberculosis and/or prophylaxis for tuberculosis.
  • Positive results to , or anti- tests.
  • Participation in any previous clinical study with BIA 9-1067.
  • Females who were pregnant according to a positive serum pregnancy test or were lactating.
  • Females of who refused to use an acceptable regimen throughout the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    5 mg BIA 9-1067

    5 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28

    Drug: BIA 9-1067 · Drug: levodopa/carbidopa · Drug: levodopa/benserazide

  • Experimental
    Placebo

    Placebo once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28.

    Drug: Placebo · Drug: levodopa/carbidopa · Drug: levodopa/benserazide

  • Experimental
    15 mg BIA 9-1067

    15 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28

    Drug: BIA 9-1067 · Drug: levodopa/carbidopa · Drug: levodopa/benserazide

  • Experimental
    30 mg BIA 9-1067

    30 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28

    Drug: BIA 9-1067 · Drug: levodopa/carbidopa · Drug: levodopa/benserazide

Interventions

  • Also known as: OPC, Opicapone

  • DrugPlacebo

    Also known as: PLC, Placebo

  • Druglevodopa/carbidopa

    Drug pages: Levodopa · Carbidopa

    Also known as: Sinemet® 100/25

  • Druglevodopa/benserazide

    Also known as: Prolopa® 100/25

06

What researchers measure

Primary outcomes

  1. Cmax - Maximum Plasma Concentration

    Cmax - maximum plasma concentration Cmax (Levodopa) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® Cmax (3-OMD) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® Cmax (BIA 9-1067) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa®

    Time frame: pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h

  2. Tmax - Time to Maximum Plasma Concentration

    Tmax - time to maximum plasma concentration Tmax (Levodopa) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® Tmax (3-OMD) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® Tmax (BIA 9-1067) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa®

    Time frame: pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h

  3. AUC0-t - Area Under the Plasma Concentration-time Curve to Last Measurable Time Point

    AUC0-t - area under the plasma concentration-time curve from time 0 to last observed concentration 3-OMD - 3-O-methyl-dopa - metabolite of L-DOPA (levodopa) AUC0-t (Levodopa) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® AUC0-t (3-OMD) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® AUC0-t (BIA 9-1067) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa®

    Time frame: pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h

  4. tEmax - Time of Occurrence of Maximum Observed Effect on S-COMT Activity

    tEmax - time of occurrence of maximum observed effect on S-COMT activity COMT - Catechol-O-Methyltransferase

    Time frame: pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h

  5. AUEC0-24 - Area Under the Effect-time Curve (AUEC) to 24 h Post-dose

    AUEC0-24 - Area under the effect-time curve (AUEC) to 24 h post-dose.

    Time frame: pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h

07

Results

Posted Nov 16, 2015

Participant flow

Participant flow — Overall Study
MilestonePlacebo5 mg BIA 9-106715 mg BIA 9-106730 mg BIA 9-1067
Started14131312
Completed12121212
Not completed2110

Outcome measures

PrimaryCmax - Maximum Plasma Concentration

Cmax - maximum plasma concentration Cmax (Levodopa) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® Cmax (3-OMD) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® Cmax (BIA 9-1067) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa®

Time frame:
pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h
Reported as:
Mean · ng/mL
Cmax - Maximum Plasma Concentration
ng/mLPlacebo5 mg BIA 9-106715 mg BIA 9-106730 mg BIA 9-1067
Cmax (Levodopa) Sinemet® 100/25985 ± 2901245 ± 5241200 ± 607944 ± 256
Cmax (Levodopa) Prolopa® 100-251704 ± 6822100 ± 9071727 ± 9571795 ± 788
Cmax (3-OMD) Sinemet® 100/25456 ± 130307 ± 106167 ± 82.5115 ± 54.5
Cmax (3-OMD) Prolopa® 100/25688 ± 230360 ± 96206 ± 110.8160 ± 61.9
Cmax (BIA 9-1067) Sinemet® 100/25NA ± NA75.0 ± 39263 ± 82.3310 ± 115
Cmax (BIA 9-1067) Prolopa® 100/25NA ± NA95.5 ± 41.1281 ± 153.4370 ± 181.7
PrimaryTmax - Time to Maximum Plasma Concentration

Tmax - time to maximum plasma concentration Tmax (Levodopa) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® Tmax (3-OMD) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® Tmax (BIA 9-1067) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa®

Time frame:
pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h
Reported as:
Median · hours
Tmax - Time to Maximum Plasma Concentration
hoursPlacebo5 mg BIA 9-106715 mg BIA 9-106730 mg BIA 9-1067
Tmax (Levodopa) Sinemet® 100/250.5 (0.5 to 3.0)0.75 (0.5 to 3.0)0.5 (0.5 to 1.5)1.0 (0.5 to 2.0)
Tmax (Levodopa) Prolopa® 100-251.0 (0.5 to 2.0)1.0 (0.5 to 1.5)1.0 (0.5 to 2.0)1.0 (0.5 to 2.0)
Tmax (3-OMD) Sinemet® 100/254.0 (4.0 to 6.0)8.0 (6.0 to 8.0)6.0 (3.0 to 8.0)8.0 (4.0 to 8.0)
Tmax (3-OMD) Prolopa® 100/254.0 (3.0 to 6.0)8.0 (4.0 to 8.0)6.0 (2.0 to 8.0)4.0 (3.0 to 8.0)
Tmax (BIA 9-1067) Sinemet® 100/25NA (NA to NA)1.5 (0.5 to 6.0)3.0 (1.5 to 6.0)4.0 (1.5 to 6.0)
Tmax (BIA 9-1067) Prolopa® 100/25NA (NA to NA)3.0 (1.0 to 4.0)2.5 (0.5 to 6.0)3.0 (1.0 to 6.0)
PrimaryAUC0-t - Area Under the Plasma Concentration-time Curve to Last Measurable Time Point

AUC0-t - area under the plasma concentration-time curve from time 0 to last observed concentration 3-OMD - 3-O-methyl-dopa - metabolite of L-DOPA (levodopa) AUC0-t (Levodopa) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® AUC0-t (3-OMD) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® AUC0-t (BIA 9-1067) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa®

Time frame:
pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h
Reported as:
Mean · ng.h/mL
AUC0-t - Area Under the Plasma Concentration-time Curve to Last Measurable Time Point
ng.h/mLPlacebo5 mg BIA 9-106715 mg BIA 9-106730 mg BIA 9-1067
AUC0-t (Levodopa) Sinemet® 100/251837 ± 5933386 ± 14492952 ± 10032753 ± 889
AUC0-t (Levodopa) Prolopa® 100-252438 ± 7124115 ± 15473442 ± 12254056 ± 1051
AUC0-t (3-OMD) Sinemet® 100/257631 ± 17865147 ± 15342836 ± 14951751 ± 988
AUC0-t (3-OMD) Prolopa® 100/2511371 ± 37076205 ± 14583473 ± 19622623 ± 1065
AUC0-t (BIA 9-1067) Sinemet® 100/25NA ± NA223 ± 58.2872 ± 4121101 ± 525
AUC0-t (BIA 9-1067) Prolopa® 100/25NA ± NA232 ± 82.4836 ± 4971185 ± 562
PrimarytEmax - Time of Occurrence of Maximum Observed Effect on S-COMT Activity

tEmax - time of occurrence of maximum observed effect on S-COMT activity COMT - Catechol-O-Methyltransferase

Time frame:
pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h
Reported as:
Mean · hours
tEmax - Time of Occurrence of Maximum Observed Effect on S-COMT Activity
hoursPlacebo5 mg BIA 9-106715 mg BIA 9-106730 mg BIA 9-1067
tEmax - Time of Occurrence of Maximum Observed Effect on S-COMT Activity8.12 ± 8.152.71 ± 2.164.67 ± 1.923.50 ± 2.41
PrimaryAUEC0-24 - Area Under the Effect-time Curve (AUEC) to 24 h Post-dose

AUEC0-24 - Area under the effect-time curve (AUEC) to 24 h post-dose.

Time frame:
pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h
Reported as:
Mean · pmol/mg Hb/h.h
AUEC0-24 - Area Under the Effect-time Curve (AUEC) to 24 h Post-dose
pmol/mg Hb/h.hPlacebo5 mg BIA 9-106715 mg BIA 9-106730 mg BIA 9-1067
AUEC0-24 - Area Under the Effect-time Curve (AUEC) to 24 h Post-dose906 ± 276454 ± 97.3319 ± 134226 ± 177

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/14 (0%)11/14 (78.6%)
5 mg BIA 9-1067—0/13 (0%)9/13 (69.2%)
15 mg BIA 9-1067—0/13 (0%)11/13 (84.6%)
30 mg BIA 9-1067—0/12 (0%)9/12 (75%)
Most frequent other events
Showing 10 of 48
Most frequent other events
EventPlacebo5 mg BIA 9-106715 mg BIA 9-106730 mg BIA 9-1067
SomnolenceNervous system disorders5/143/135/136/12
HeadacheNervous system disorders2/141/131/133/12
DizzinessNervous system disorders2/143/131/131/12
Disturbance in attentionNervous system disorders0/140/130/132/12
Ocular hyperaemiaEye disorders1/141/132/130/12
Abdominal painGastrointestinal disorders0/142/130/131/12
DiarrhoeaGastrointestinal disorders2/142/132/131/12
FatigueGeneral disorders1/140/132/131/12
RashSkin and subcutaneous tissue disorders1/140/132/131/12
NauseaGastrointestinal disorders2/141/131/131/12

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Placebo5 mg BIA 9-106715 mg BIA 9-106730 mg BIA 9-1067Total
<=18 years00000
Between 18 and 65 years1413131252
>=65 years00000
Sex: Female, Male
Sex: Female, Male(Participants)Placebo5 mg BIA 9-106715 mg BIA 9-106730 mg BIA 9-1067Total
Female766625
Male777627
08

Study locations

1 site
  • Algorithme Pharma Inc.
    Mount-Royal, Quebec H3P 3P1, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Aug 2009 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 6 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2012
First posted
Feb 15, 2012
Start
Mar 2009
Primary completionActual
Aug 2009
CompletionActual
Mar 2010
Results first posted
Nov 16, 2015
Last update
Nov 16, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01533116
Responsible party
Sponsor
First posted
Feb 15, 2012
Start date
Mar 2009
Primary completion
Aug 2009
Completion
Mar 2010
Results posted
Nov 16, 2015
Last update
Nov 16, 2015

Study contacts

Eric Sicard, MD
principal investigator · Algorithme Pharma Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Opicapone · Levodopa · Carbidopa

Start the discussion